Prospective, open-label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study

The OPTIM1SE study observed long-term real-world outcomes of cetuximab-based infusional 5-fluorouracil (5-FU) regimens for first-line treatment of metastatic colorectal cancer (mCRC) across Asia-Pacific and Middle East regions, aiming to characterize their use, effectiveness, and safety in routine p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Asia-Pacific journal of clinical oncology 2023-12, Vol.19 (6), p.672-680
Hauptverfasser:	Yang, Tsai-Sheng, Chen, Hong-Hwa, Bo-Wen, Lin, Kim, Tae Won, Kim, Jong Gwang, Ahn, Joong Bae, Lee, Myung-Ah, Lin, Johnson, Ho, Gwo Fuang, Anh, Le Tuan, Temraz, Sally, Burge, Matthew, Chua, Clarinda, Huang, Jason, Park, Young Suk
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Antineoplastic Combined Chemotherapy Protocols - adverse effects Camptothecin - therapeutic use Cetuximab - therapeutic use Colonic Neoplasms Colorectal carcinoma Colorectal Neoplasms - pathology Electronic medical records Female Fluorouracil - adverse effects Humans Irinotecan Leucovorin - adverse effects Liver diseases Liver Neoplasms - drug therapy Male Metastases Metastasis Middle Aged Observational studies Oxaliplatin Patients Prospective Studies Proto-Oncogene Proteins p21(ras) - therapeutic use Rectal Neoplasms Safety Survival Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!